Crown Laboratories

What Crown Laboratories does

Crown Laboratories, founded in 2000 and headquartered in Johnson City, Tennessee, is a privately held specialty pharmaceutical company that develops, manufactures, and commercializes dermatology, aesthetics, and consumer skincare products across three operating segments: Aesthetics (SkinPen and MicroPen EVO microneedling devices, ProGen PRP Eclipse platelet-rich plasma systems, DAXXIFY neuromodulator, and Teoxane RHA Collection dermal fillers sold to medical practices), Consumer Skincare (StriVectin, PanOxyl, Blue Lizard Australian Sunscreen, BIOJUVE, Sarna, Keri, Zeasorb, and Desenex sold through mass-market retail and e-commerce), and Prescription dermatology products (Triderm, ALA-CORT, Nystatin) sold through pharmacies, with a complementary CDMO services offering.

The company's underlying technology rests on a portfolio of proprietary platforms including NIA-114 (a patented optimized niacin/vitamin B3 used across all StriVectin formulas), Xycrobe living microbe technology built on Cutibacterium acnes defendens strain XYCM42 (the basis for the BIOJUVE skin biome franchise), ActiSine active retraction technology in the SkinPen Precision Elite, and the peptide-formulated DAXXIFY neurotoxin. Manufacturing is anchored in a 250,000 sq ft FDA-certified, cGMP-compliant facility in Johnson City, TN, which also serves third-party CDMO customers. Distribution spans 60 countries through a combination of a direct aesthetics field sales force, major retail and e-commerce channels (Amazon, Target, Walmart, drugstores), and exclusive U.S. distribution rights for Teoxane.

Following its 2017 acquisition by Hildred Capital Partners and a programmatic series of acquisitions (Bellus Medical, Xycrobe Therapeutics, StriVectin, Eclipse MedCorp, Healeon, and Revance Therapeutics), the company employs more than 750 people across Johnson City, Dallas, and New York. The February 2025 close of the $924 million Revance Therapeutics acquisition and subsequent March 2025 rebranding to operate under the Revance name transformed the business into a multi-brand, multi-channel aesthetics and skincare platform with reported 91% three-year revenue growth (2021-2024) and a 12th Inc. 5000 appearance in 2025.

Name

Crown Laboratories

Legal name

Crown Laboratories, Inc.

Website

https://crownlaboratories.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

251–500 employees

Short description

Crown Laboratories, now operating as Revance, is a privately held specialty pharmaceutical and aesthetics company that develops and commercializes FDA-cleared medical devices, injectables, prescription dermatology, and consumer skincare brands across more than 60 countries.

Ownership category

akta.pro rank

Product category

Dermatology and Aesthetics Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Health and Personal Care Retailers (456)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industry

Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Specialty pharmaceuticals
• Aesthetics medical devices
• Consumer skincare brands
• Microneedling technology
• Dermatology therapeutics

Headquarters

HQ city

Johnson City

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Aesthetics Products: Sales of SkinPen microneedling devices, ProGen PRP systems, and related aesthetic medical devices to practitioners. Also includes DAXXIFY neurotoxin and RHA dermal fillers following the Revance acquisition.
2. Consumer Skincare Products: Sales of consumer skincare brands including StriVectin, PanOxyl, Blue Lizard, Sarna, Keri, Zeasorb, Desenex, and BIOJUVE through retail and e-commerce channels.
3. Prescription and Therapeutic Products: Sales of prescription dermatology products including Triderm, ALA-CORT, Nystatin Cream, and generic products to healthcare providers and patients.
4. Contract Development and Manufacturing Services: CDMO services provided to third parties through Crown's 250,000 sq ft FDA-certified, cGMP-compliant facility in Johnson City, TN. Supports development and manufacturing of liquid and semi-solid products.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

Crown Laboratories is a fully integrated specialty pharmaceutical company that develops, manufactures, and commercializes aesthetics medical devices, neuromodulator injectables, dermal fillers, prescription dermatology products, and consumer skincare brands. The company sells aesthetics products (SkinPen, DAXXIFY, ProGen PRP, Teoxane RHA fillers) directly to medical practices while distributing consumer skincare brands (StriVectin, PanOxyl, Blue Lizard, BIOJUVE, Sarna, Keri) through retail, e-commerce, and direct-to-consumer channels across 60 countries.

Product overview

Crown Laboratories operates as a diversified pharmaceutical and consumer skincare company with three main business segments: Aesthetics (medical devices and injectable products), Consumer Skincare (OTC and prescription dermatology brands), and Contract Development & Manufacturing (CDMO) services. The aesthetics portfolio includes FDA-cleared microneedling devices (SkinPen, MicroPen EVO), platelet-rich plasma systems (ProGen PRP), the neuromodulator DAXXIFY, and Teoxane RHA dermal fillers. The consumer skincare segment encompasses well-known brands like StriVectin (anti-aging), PanOxyl (acne), Blue Lizard (sunscreen), Sarna (itch relief), and various antifungal products. The company also offers prescription dermatology products and CDMO manufacturing services.

Differentiator

Problem solved

Functional benefit

Brands

• StriVectin: Premium skincare brand powered by patented NIA-114 technology for aging and changing skin
• PanOxyl
• Blue Lizard Australian Sunscreen
• Sarna
• Keri
• Zeasorb
• Desenex
• BIOJUVE
• SkinPen
• ProGen PRP Eclipse
• DAXXIFY
• Teoxane RHA Collection

Products and services

• SkinPen
• SkinPen Precision Elite
• ProGen PRP Eclipse
• DAXXIFY
• Teoxane RHA Collection
• StriVectin
• PanOxyl
• Blue Lizard Australian Sunscreen
• BIOJUVE
• Sarna
• Sarna Eczema Relief Skin Protectant Lotion
• Keri
• Zeasorb
• Desenex
• Blue Lizard After Sun Soothing Lotion
• Triderm
• ALA-CORT
• Nystatin Cream
• Hydrocortisone Cream USP
• Contract Development and Manufacturing (CDMO) Services

Quantifiable outcome

• SkinPen is the first FDA-cleared microneedling device and the number one microneedling brand in the United States
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Five partnerships are on record, tiered flagship, minor and core.

• Revance TherapeuticsflagshipStrategic or Co-development Partner · 12 August 2024Crown Laboratories merged with and acquired Revance Therapeutics in February 2025 for approximately $924 million. The acquisition brought DAXXIFY neurotoxin, RHA dermal fillers, and additional aesthetics capabilities. The combined company now operates under the Revance name.
• Healeon LLC (Bimini Health Tech)minorStrategic or Co-development Partner · 23 July 2024Crown acquired select assets from Healeon LLC, a subsidiary of Bimini Health Tech, a global leader in innovative medical devices. Details of specific products acquired not specified.
• Teoxane SAcoreChannel Partner/ Reseller/ Distributor · 27 August 2023Revance is an independent distributor of Teoxane SA to supply the RHA Collection of dermal fillers to the U.S. market. RHA technology is proprietary to and manufactured in Switzerland by Teoxane SA. The partnership was expanded in 2025 with launch of RHA Collection with Mepivacaine.
• StriVectinflagshipStrategic or Co-development Partner · 26 August 2021Crown acquired StriVectin, a leading independent prestige skincare brand in the U.S., integrating it into Crown's Premium Skincare Division. StriVectin brings patented NIA-114 technology and over 35 years of clinical research.
• East Tennessee State University (ETSU)minorStrategic or Co-development Partner · 1 August 2021Crown launched the CLERI (Crown Laboratories Educational Research Initiative) program in collaboration with ETSU exploring changes to skin microbiome treatment. Dr. Thomas Hitchcock and Dr. Mun Su Rhee appointed as adjunct faculty at ETSU Department of Biomedical Sciences.

Scale indicators8 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Galderma: Galderma is a global dermatology-focused company with leading aesthetics franchises (Restylane fillers, Sculptra biostimulator, Dysport neurotoxin) and consumer/therapeutic skincare. It is the most direct competitor to Revance's combined aesthetics + dermatology platform and a benchmark for PE-backed dermatology exits (Galderma IPO'd in 2024).
• Merz Aesthetics: Merz Aesthetics markets Xeomin (neurotoxin), Belotero (HA filler), Radiesse (biostimulator), and Ultherapy (energy device). It is a direct peer in medical aesthetics devices and injectables, competing head-to-head with DAXXIFY, RHA, and SkinPen.
• Evolus: Evolus markets Jeuveau (prabotulinumtoxinA), a competing neurotoxin to DAXXIFY and Botox. It is a focused, pure-play aesthetics peer with a similar commercial strategy of targeting younger patients and switching from entrenched incumbents—making it a relevant direct comp on the neurotoxin side.
• Obagi Medical: Obagi is a medical-grade skincare company offering physician-dispensed products for anti-aging, hyperpigmentation, and acne. It competes directly with StriVectin, BIOJUVE, and the prescription/therapeutic skincare lines. It was also PE-owned (Valeant/BMGC) and serves as a useful comparable for exit dynamics.
• Revision Skincare: Revision Skincare is a physician-dispensed premium skincare brand focused on anti-aging and skin health, sold through medical practices. It directly competes with StriVectin in the professional channel and shares the same physician sales force motion.
• EltaMD: EltaMD is a leading mineral and broad-spectrum sunscreen brand widely used and recommended by dermatologists, directly competing with Blue Lizard Australian Sunscreen. Now owned by Colgate-Palmolive, it serves as both a competitive benchmark and an analog for consumer dermatology brand exit multiples.

Broad incumbents

• AbbVie (Allergan Aesthetics): AbbVie's Allergan Aesthetics division houses Botox, Juvéderm, CoolSculpting, Latisse, and SkinMedica. It is the dominant incumbent in neurotoxins and hyaluronic acid fillers against which DAXXIFY and the RHA Collection directly compete, and SkinMedica competes in medical-grade skincare alongside StriVectin.
• SkinMedica (Allergan): SkinMedica is Allergan Aesthetics' physician-dispensed skincare line, including the TNS growth factor platform. It competes with StriVectin and BIOJUVE in the medical-grade skincare category, and is part of a much larger incumbent (AbbVie/Allergan) that bundles it with Botox/Juvéderm practices.
• CeraVe (L'Oréal): CeraVe, owned by L'Oréal, is the #1 dermatologist-recommended skincare brand in the US and competes in mass and prestige channels with StriVectin, PanOxyl, and other consumer brands. It represents the scale competitive threat in consumer dermatology that Crown/Revance's brands must navigate.

Emerging players

• Hugel America (Botulax/Letybo): Hugel is a South Korean biopharmaceutical company with the Letybo/Botulax neurotoxin (FDA-approved in the US in 2024). As another emerging neurotoxin entrant alongside DAXXIFY and Jeuveau, it represents competitive pressure on DAXXIFY's positioning against Botox in the US market.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/OneCrownLabs
• Facebookfacebook.com/Crown-Laboratories-1540200579635843
• LinkedInlinkedin.com/company/crown-laboratories-inc-
• Instagraminstagram.com/crownlaboratories

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries15 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Crown Laboratories